--A French subsidiary of pharmaceutical company Merck KGaA is facing further investigations in France for potentially misleading information related to a change in formula of its thyroid medication Levothyrox, news agency AFP reports.

--The unit said investigations aren't related to the quality of the new formula but communications related to the change in 2017, AFP reports.

--Shares in Merck KGaA are down 4% at EUR164.70.

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

October 19, 2022 05:17 ET (09:17 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 5 2024 まで 6 2024 Merck KGaA (PK)のチャートをもっと見るにはこちらをクリック
Merck KGaA (PK) (USOTC:MKKGY)
過去 株価チャート
から 6 2023 まで 6 2024 Merck KGaA (PK)のチャートをもっと見るにはこちらをクリック